Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019

Autor: Wenbin Li, PhD, Yunfeng Lyu, PhD, Shaoming Wang, PhD, Xiaoyan Zhou, MD, PhD, Jie Ma, MD, Chao Xu, MS, Li Fang, MS, Jianming Ying, MD, PhD, Lei Guo, Tian Qiu, Weihua Li, Yan Li, Nanying Che, Xuefeng Bai, Yanfeng Xi, Yanping Hu, Liping Liu, Xuemei Li, Shujun Zhang, Hongxue Meng, Xiumei Duan, Yan Wu, Lian He, Nan Liu, Jie He, Hong Li, Zhihui Yang, Jie Lin, Yi Shi, Xiaoyan Li, Meihong Yao, Qianming Bai, Ling Xie, Xinghua Zhu, Aiyan Xing, Zebing Liu, Lei Dong, Wentao Huang, Jie Huang, Guohua Yu, Xiaotong Hu, Dan Su, Bing Wei, Fang Guo, Ziguang Xu, Guozhong Jiang, Qian Cui, Jia Li, Xianhua Xu, Juan Jiao, Xinhui Fu, Nengtai Ouyang, Xiaojuan Li, Xiaoying Zhu, Yanjie Liu, Qiushi Wang, Qiong Liao, Zhuo Zuo, Tao Luo, Chenggang Yang, Xiaoming Wang, Xi Liu, Wenli Cui

Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 4, Pp 100163- (2021)

Introduction: Lung cancer is the leading cause of cancer-related morbidity and mortality in the People’s Republic of China. Targeted therapies for patients with lung cancer, which depend on accurate identification of actionable genomic alteration,

Externí odkaz: https://doaj.org/article/bf4a443817d748a39725c0d958e4f8e9